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Abstract
Primary antibody deficiencies present clinically as reduced or absent plasma antibodies without another identified disorder
that could explain the low immunoglobulin levels. Bone marrow-liver-thymus (BLT) humanized mice also exhibit primary
antibody deficiency or hypogammaglobulinemia. Comprehensive characterization of B cell development and differentiation
in BLT mice revealed other key parallels with primary immunodeficiency patients. We found that B cell ontogeny was
normal in the bone marrow of BLT mice but observed an absence of switched memory B cells in the periphery. PC-KLH
immunizations led to the presence of switched memory B cells in immunized BLT mice although plasma cells producing PC-
or KLH- specific IgG were not detected in tissues. Overall, we have identified the following parallels between the humoral
immune systems of primary antibody deficiency patients and those in BLT mice that make this in vivo model a robust and
translational experimental platform for gaining a greater understanding of this heterogeneous array of humoral
immunodeficiency disorders in humans: (i) hypogammaglobulinemia; (ii) normal B cell ontogeny in bone marrow; and (iii)
poor antigen-specific IgG response to immunization. Furthermore, the development of strategies to overcome these
humoral immune aberrations in BLT mice may in turn provide insights into the pathogenesis of some primary antibody
deficiency patients which could lead to novel clinical interventions for improved humoral immune function.
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Introduction
Primary antibody deficiencies are characterized by reduced or
absent plasma antibody levels when no other disorder can be
identified as causing the immunoglobulin deficits [1,2]. There are
three major forms of primary antibody deficiency including X-
linked or Bruton’s agammaglobulinemia and selective IgA
deficiency [1,2]. The third and most frequently diagnosed form
of this disease is common variable immunodeficiency (CVID) [3–
5]. Both females and males are diagnosed with CVID, often
during the second or third decade of life [6,7]. Primary antibody
deficiency in CVID results from aberrant B cell differentiation that
could be due to many various genetic defects which may affect T,
B and potentially other cells [3–5,8–11]. Hypogammaglobulin-
emia in CIVD patients is manifested as profound reduction in
serum IgG and low serum IgA, frequently accompanied by
reduced serum IgM [12]. Clinical symptoms in these individuals
include lymphoproliferation, recurrent respiratory bacterial infec-
tions (e.g., sinusitis, otitis media, bronchitis, and pneumonia),
chronic diarrhea, granulomatous disease, autoimmune phenome-
na (e.g. immune thrombocytopenic purpura), malignancy and/or
hepatitis [7,13,14]. Current standard of care for primary antibody
deficiency patients is passive immunoglobulin transfer and
treatment of recurrent infections with antimicrobials [15].
Due to the heterogeneous etiologies of primary antibody
deficiency, these disorders are challenging to study in patients
and to model in vivo. Patient-based research is primarily focused
on peripheral blood analyses and is inherently accompanied by
limitations that impede achieving adequately powered patient
groups with specific diagnoses, especially given the factors which
may preclude sufficient patient recruitment from within pediatric
and adolescent populations [6,7,16,17]. Moreover, effective
translation of data from current mouse primary antibody
deficiency models to human conditions has been limited by well
described differences in the development and function of mouse B
cells versus human B cells (reviewed in [18–20]). Nevertheless, a
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robust in vivo model of human primary antibody deficiency would
serve two major purposes. First, the model would bolster efforts to
understand the mechanisms responsible for the B cell compart-
ment abnormalities in patients. Second, strategies to improve
antibody production in primary antibody deficiency in patients
could be evaluated in such a model for pre-clinical efficacy.
Humanized mice have the potential to serve as such a model.
Humanized mice harbor de novo generated human immune cells
that form a functional human immune system within each animal.
Bone marrow-liver-thymus (BLT) humanized mice are generated
by implantation of human thymus and liver tissues beneath the
kidney capsule of immunodeficient mice followed by transplanta-
tion with autologous human CD34+ hematopoietic stem cells
[21,22]. BLT mice harbor robust levels of human hematopoietic
cells (e.g. T cells, B cells, monocytes/macrophages and dendritic
cells) throughout their body [22–26]. BLT mice have been
extensively used for modeling HIV disease and other human
specific conditions (reviewed in [27]). Nevertheless, humanized
mice in general have exhibited relatively poor B cell function and
rudimentary secondary lymphoid structure formation
[21,22,25,28–40]. Given the deficient humoral immune responses
in humanized mice, despite their otherwise remarkable recapitu-
lation of the human immune system’s development and function,
we examined the potential for BLT mice to serve as a primary
antibody deficiency model. To do this we compared the human B
cell development, differentiation and function we observed in BLT
mice to literature detailing primary antibody deficiency in patients.
Methods
Ethics
Mice were maintained under specific pathogen-free conditions
in accordance with protocols approved by the University of Texas
Southwestern Medical Center at Dallas Institutional Animal Care
Figure 2. BLT mouse peripheral blood harbors few unswitched and switched memory B cells relative to adult human peripheral
blood. (A–B) Representative flow cytometry analyses for CD27 and IgD expression on B cells in adult human PB and BLT mouse PB shows a paucity
of unswitched/switched memory B cells in BLT mouse blood. (adult PB, n = 5; BLT PB, n = 18). (C–D) Flow cytometry plots and bar graph for CD38 and
IgD expression on CD19+ cells reveal an absence of switched memory B cell populations in BLT mouse PB while these populations are present in adult
human PB (adult PB, n = 5; BLT PB n = 16). * indicates a p value less than 0.05. ** indicates a p value less than 0.01. *** indicates a p value less than
0.001. Comprehensive statistical analyses are presented in Table 1.
doi:10.1371/journal.pone.0108663.g002
Figure 1. BLT humanized mice exhibit profound plasma hypogammaglobulinemia. (A) BLT mouse plasma (n = 13) was collected and
analyzed by ELISA for the presence of human IgM, IgA and IgG. Log transformed plasma Ig levels in BLT mice are plotted on a linear y-axis and shown
superimposed over the mean (center horizontal line) and 95% range (shaded area) Ig values from adult humans. (B) At harvest, ELISPOT analyses for
plasma cells were performed with mononuclear cells isolated from the indicated tissues of BLT mice (n = 4). Statistical comparisons were 1 way
ANOVA with Bonferroni’s multiple comparisons tests. Plot colors are matched to the colors in (A). * indicates a p value less than 0.05. ** indicates a p
value less than 0.01. *** indicates a p value less than 0.001. (C) Sections from the spleens (left) and lymph nodes (right) of BLT mice analyzed for
lymphoid architecture via H&E staining. BALB/c tissues were included as positive controls for the appearance of normal immune structures. Scale bars
= 50 mm in all images. Boxes indicate the areas that are shown at higher magnification in the images below.
doi:10.1371/journal.pone.0108663.g001
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and Use Committee in the UT Southwestern Animal Resources
Center or in accordance with protocols approved by the
University of North Carolina at Chapel Hill Institutional Animal
Care and Use Committee in the UNC-CH Division of Laboratory
Animal Medicine.
Generation of BLT humanized mice, plasma
immunoglobulin ELISA, PC-KLH immunization and
plasma cell ELISPOT analyses
NOD/SCID IL-2Rc-/- (NOD.Cg-Prkdcscid Il2rctm1Wjl/Szj;
NSG) and BALB/c mice were obtained from The Jackson
Laboratory. BLT mice were bioengineered with de-identified
human tissues essentially as previously described [22,24,41].
Briefly, human fetal liver CD34+ cells were transplanted into
preconditioned NSG mice implanted with autologous liver and
thymus (Advanced Bioscience Resources). Peripheral blood
plasma levels of human IgM, IgG and IgA in naı¨ve BLT mice
were measured by ELISA. In brief, 96-well ELISA plates (Thermo
Scientific, Rochester NY) were coated with anti-human IgM, IgG
or IgA antibodies (Bethyl Laboratories, Montgomery, TX)
overnight at 4uC. After blocking with 1% BSA for 1 hour at
room temperature (RT), the plates were treated with diluted
plasma for 2 hours at RT and HRP-conjugated anti-human IgM,
IgG or IgA antibodies (SouthernBiotech, Birmingham, AL) were
then treated for 1 hour at RT. The reaction was developed with a
TMB Microwell Peroxidase Substrate System (XPL, Gaithers-
burg, MD). Purified human IgM, IgG and IgA (Sigma, St Louis,
MO) were used as standards.
BLT mice were immunized intraperitoneally with 100 mg of
PC-KLH (Biosearch Technologies, Petaluma, CA) every other
week for a total of four immunizations. Cholera toxin (1 mg) was
used as an adjuvant (List Biological Laboratories, Campbell, CA).
Antigen specific IgM and IgG were measured by ELISA and
ELISPOT analyses. For ELISA analysis, 96-well ELISA plates
were first pre-coated with PC-BSA (Biosearch Technologies,
Petaluma, CA) or KLH (Sigma) overnight at 4uC, then the wells
were blocked with 1% BSA. Following a 2 hour incubation with
BLT mouse plasma at RT, wells were washed and treated with
HRP-conjugated anti-human IgM or IgG antibodies for 1 hour at
RT. Signal was developed with a TMB Microwell Peroxidase
Substrate System. For the ELISPOT analysis, one week after the
fourth immunization, bone marrow, spleen, lymph nodes, liver
and lung were harvested from immunized BLT mice. Mononu-
clear cells were isolated from these tissues as we previously
described [22–25] and evaluated by ELISPOT analysis for their
antigen-specific Ig production. ELISPOT plates (EMD Millipore,
Billerica, MA) were first pre-coated with PC-BSA or KLH
overnight at 4uC. Cells freshly isolated from tissues of immunized
BLT mice were suspended in RPMI-1640 containing 10% FBS,
100 I.U. penicillin and 100 mg/ml streptomycin and then 16105
cells in a total of 100 ml media were seeded per well and cultured
for 4 hours in a 5% CO2 incubator. After washing, the wells were
treated with HRP-conjugated anti-human IgM or IgG antibodies
(SouthernBiotech) overnight at 4uC and the signals were then
developed using AEC substrate (Sigma). Antibody positive cells
were enumerated with an AID ELISPOT Reader System ELR04
(Strassberg, Germany).
Human B cell flow cytometry panels
Flow cytometry data were collected using a BD FACSCanto
cytometer and analyzed using BD FACSDiva software (v. 6.1.3).
Flow cytometry antibody panels for analysis of B cells in BLT mice
were: Panel A – IgD FITC (IA6-2), CD27 PE (L128), CD38
PerCP (HIT2), CD19 PE-Cy7 (SJ25C1), CD5 APC (UCHT2),
CD45 APC-Cy7 (2D1); Panel B – TdT or IgG1 control FITC
(HTdT-6; Supertechs), CD22 or IgG1k control PE (H1B22;
Biolegend), CD20 PerCP (2H7), CD19 PE-Cy7 (SJ25C1), CD10
APC (H110a), CD45 APC-Cy7 (2D1); Panel C – CyIgM or IgG1k
control FITC (G20-127), Cyl5 or IgG1k control PerCP (courtesy
of Dr. H. Karasuyama; Tokyo Medical and Dental University),
CD19 PE-Cy7 (SJ25C1), CD10 APC (H110a), CD45 APC-Cy7
(2D1). Antibodies were purchased from BD Biosciences unless
otherwise noted.
Table 1. Comparison of B cell populations between BLT mouse and adult human peripheral blood using CD27/IgD and CD38/IgD
co-expression patterns.
BLT mouse PB Adult human PB t-test
CD27/IgD Immature B/Atypical switched memory B 19.6611.9 (n = 16) 3.761.9 (n = 5) ,0.01
Transitional B/Mature Naı¨ve B 75.4613.0 (n = 16) 63.9618.3 (n = 5) n.s.
Unswitched Memory B 2.861.5 (n = 16) 15.069.4 (n = 5) ,0.001
Switched Memory IgM+ B/Plasmablasts 2.361.9 (n = 16) 17.468.6 (n = 5) ,0.001
CD38/IgD CD38neg IgD+ 5.062.8 (n = 16) 12.5613.6 (n = 5) ,0.05
CD38+ IgD+ 50.5613.6 (n = 16) 56.8617.5 (n = 5) n.s.
CD38++ IgD+ 22.865.3 (n = 16) 10.065.3 (n = 5) ,0.001
CD38++ IgDneg 21.1612.2 (n = 16) 1.660.9 (n = 5) ,0.01
CD38+ IgDneg 1.360.7 (n = 16) 12.665.7 (n = 5) ,0.001
CD38neg IgDneg 0.561.3 (n = 16) 7.764.9 (n = 5) ,0.001
Data presented as Mean 6 SD.
n.s. = not significantly different.
Immature B/Atypical switched memory B = CD27neg IgDneg.
Naı¨ve Mature B = CD27neg IgD+.
Transitional B/Mature Naı¨ve B = CD27+ IgD+.
Switched Memory IgM+ B/Plasmablasts = CD27+ IgDneg.
doi:10.1371/journal.pone.0108663.t001
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Figure 3. B cell ontogeny in the bone marrow of BLT mice follows canonical patterns. (A–B) Flow cytometry and scatter plots reveal the
relative paucity of mature B cells in the BM as defined according to CD10 and CD20 expression. (n = 15; 1 way ANOVA with Bonferroni’s multiple
comparisons tests). (C–D) Flow cytometry and scatter plots reveal that, as expected, immature B cells exhibited higher levels intracellular TdT
expression, a protein that is active during B cell receptor rearrangement. (n = 15; 1 way ANOVA with Bonferroni’s multiple comparisons tests). (E–F)
Flow cytometry and scatter plots for CD10 expression show that the majority of BLT mouse BM CD19+ cells are Pre-B/Immature B cells. (n = 13, t-test).
(G–H) More BLT mouse Pre-B/Immature B cells identified in (E–F) express the pre-B cell receptor surrogate light chain component lambda 5 than
CD10neg mature B cells. (n = 4, t-test). (I–J) Conversely, more CD10neg mature B cells expressed intracellular IgM than did the Pre-B/Immature B cells
present in BLT mouse BM (n = 13, t-test). ** indicates a p value less than 0.01. *** indicates a p value less than 0.001.
doi:10.1371/journal.pone.0108663.g003
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Histological analyses
Tissues for histology were harvested from BLT and BALB/c
mice, fixed in 4% paraformaldehyde for 24 hours at 4uC,
embedded in paraffin, cut into 5 mm sections and mounted onto
poly-L-lysine coated glass slides. Following paraffin removal,
sections were stained with Mayer’s hematoxylin and eosin (H&E)
for analysis. Images were taken with an upright Nikon Microphot
SA microscope with a DXM 1200 color camera and the white
balance and brightness adjusted in Adobe Photoshop CS4.
Statistics
Plots and descriptive statistics were generated in Prism v5 or v6
(Graph Pad). Values in text are presented as: (mean percent6
standard deviation).
Results
BLT mice exhibit profound hypogammaglobulinemia
To bioengineer BLT humanized mice, human fetal liver CD34+
cells were transplanted into preconditioned NSG mice implanted
with autologous liver and thymus. In total, 55 BLT mice generated
using 20 different human donors were utilized herein. Peripheral
blood human chimerism was assessed by flow cytometry in each
BLT humanized mouse prior to use (week 1664 weeks post-BLT
humanization) [22,23,25,26,41–49]. We observed that 58%
(621%) of cells expressed hCD45; 42% (619%) of hCD45+ cells
also expressed hCD19; 43% (623%) of hCD45+ cells also
expressed hCD3 and 81% (67%) of hCD3+ cells also expressed
hCD4. To establish baseline characteristics of human Ig produc-
tion in this model, we performed a longitudinal characterization of
peripheral blood (PB) plasma levels of human IgM, IgA and IgG in
BLT mice (n = 13) in the absence of a specific antigenic stimulus
(referred to as ‘‘naı¨ve’’ BLT mice). These values were then
compared to 95% ranges for adult human levels for these
immunoglobulins: IgM = 0.56–3.52 g/L; IgA = 0.70–3.12 g/L;
and IgG = 6.39–13.49 g/L [50]. Human IgM, human IgA and
human IgG were all detected in BLT mice; however, their titers all
remained below the human 95% range throughout the observa-
tion period (Figure 1A). To gain insights into the tissue source(s) of
the antibodies present in BLT mouse plasma, we used ELISPOT
analyses to quantitate the numbers of IgM, IgA and IgG
producing plasma cells generating human antibodies in bone
marrow (BM), spleen, lymph nodes (LN), liver and lungs. The
results showed that there were more IgM-producing cells than
IgA-producing and IgG-producing cells in BM, spleen, LN and
liver (Figure 1B). Furthermore, we observed a lack of white pulp
with germinal centers in the spleen and a lack of clear distinctions
between the light and mantle zones in LN (Figure 1C) [51].
Despite this atypical tissue architecture in the spleen and LN,
which could hinder isotype switching in B cells, these secondary
lymphoid organs tissues were found to harbor the highest numbers
of IgM, IgA and IgG plasma cells (Figure 1B).
Classical Memory B cells were rare in the peripheral
blood of BLT mice
We used complementary immunophenotyping strategies for
assessing B cell differentiation. These strategies included examin-
ing combined surface expression patterns of: CD27 and IgD as
markers of memory and maturation [52–54] and CD38 and IgD
as classical clinical markers for distinguishing memory B cell
subpopulations [53]. Using CD27 and IgD co-expression
patterns, B cells were defined as immature/atypical switched
memory B cells (CD27negIgDneg), transitional and mature naı¨ve
(CD27negIgD+), classical unswitched memory (CD27+IgD+), and
classical switched memory IgM and plasmablasts (CD27+IgDneg)
Figure 4. Most B cells in BLT mouse tissues exhibit an immature phenotype. (A–B) Flow cytometry plots and bar graph for CD27 and IgD
expression on B cells reveal an absence of unswitched/switched memory B cells in BLT mouse BM, spleen, LN, liver and lungs (n = 5 for all tissues). (C–
D) Flow cytometry plots and bar graph for CD38 and IgD expression on CD19+ cells reveal an absence of switched memory B cell populations in BLT
mouse tissues (n = 5 for all tissues). * indicates a p value less than 0.05. ** indicates a p value less than 0.01. *** indicates a p value less than 0.001.
Comprehensive statistical analyses are presented in Table 2.
doi:10.1371/journal.pone.0108663.g004
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Table 2. B cell populations in BLT mice according to CD27/IgD and CD38/IgD co-expression patterns.
Tissue BLT Mice
1 way ANOVA Bonferroni’s multiple comparisons
tests
CD27/IgD Immature B/Atypical switched memory B BM 85.768.8 (n = 5) BM vs. Spleen: ,0.001 Spleen vs. Liver: n.s.
Spleen 38.2610.3 (n = 5) BM vs. LN: ,0.001 Spleen vs. Lung: ,0.01
LN 11.069.4 (n = 5) BM vs. Liver: ,0.001 LN vs. Liver: ,0.01
Liver 34.867.6 (n = 5) BM vs. Lung: ,0.001 LN vs. Lung: n.s.
Lung 13.963.5 (n = 5) Spleen vs. LN: ,0.001 Liver vs. Lung: ,0.01
Transitional B/Mature Naı¨ve B BM 13.568.7 (n = 5) BM vs. Spleen: ,0.001 Spleen vs. Liver: n.s.
Spleen 59.869.2 (n = 5) BM vs. LN: ,0.001 Spleen vs. Lung: ,0.01
LN 81.3611.2 (n = 5) BM vs. Liver: ,0.001 LN vs. Liver: ,0.05
Liver 63.567.7 (n = 5) BM vs. Lung: ,0.001 LN vs. Lung: n.s.
Lung 84.265.7 (n = 5) Spleen vs. LN: ,0.01 Liver vs. Lung: ,0.05
Unswitched Memory B BM 0.160.1 (n = 5) BM vs. Spleen: n.s. Spleen vs. Liver: n.s.
Spleen 1.261.0 (n = 5) BM vs. LN: ,0.01 Spleen vs. Lung: n.s.
LN 3.061.7 (n = 5) BM vs. Liver: n.s. LN vs. Liver: ,0.01
Liver 0.560.2 (n = 5) BM vs. Lung: n.s. LN vs. Lung: ,0.05
Lung 0.760.7 (n = 5) Spleen vs. LN: n.s. Liver vs. Lung: n.s.
Switched Memory IgM+ B/Plasmablasts BM 0.660.3 (n = 5) BM vs. Spleen: n.s. Spleen vs. Liver: n.s.
Spleen 3.760.6 (n = 5) BM vs. LN: n.s. Spleen vs. Lung: n.s.
LN 4.764.9 (n = 5) BM vs. Liver: n.s. LN vs. Liver: n.s.
Liver 1.360.8 (n = 5) BM vs. Lung: n.s. LN vs. Lung: n.s.
Lung 1.362.0 (n = 5) Spleen vs. LN: n.s. Liver vs. Lung: n.s.
CD38/IgD CD38neg IgD+ BM 0.160.1 (n = 5) BM vs. Spleen: n.s. Spleen vs. Liver: n.s.
Spleen 0.660.4 (n = 5) BM vs. LN: n.s. Spleen vs. Lung: n.s.
LN 0.560.4 (n = 5) BM vs. Liver: n.s. LN vs. Liver: n.s.
Liver 0.660.4 (n = 5) BM vs. Lung: ,0.01 LN vs. Lung: n.s.
Lung 1.360.8 (n = 5) Spleen vs. LN: n.s. Liver vs. Lung: n.s.
CD38+ IgD+ BM 6.964.5 (n = 5) BM vs. Spleen: ,0.01 Spleen vs. Liver: n.s.
Spleen 37.169.5 (n = 5) BM vs. LN: ,0.001 Spleen vs. Lung: n.s.
LN 73.2617.7 (n = 5) BM vs. Liver: ,0.001 LN vs. Liver: ,0.01
Liver 43.2610.0 (n = 5) BM vs. Lung: ,0.001 LN vs. Lung: n.s.
Lung 59.6611.1 (n = 5) Spleen vs. LN: ,0.001 Liver vs. Lung: n.s.
CD38++ IgD+ BM 6.864.4 (n = 5) BM vs. Spleen: ,0.01 Spleen vs. Liver: n.s.
Spleen 24.262.7 (n = 5) BM vs. LN: n.s. Spleen vs. Lung: n.s.
LN 11.769.0 (n = 5) BM vs. Liver: ,0.05 LN vs. Liver: n.s.
Liver 21.464.0 (n = 5) BM vs. Lung: ,0.01 LN vs. Lung: ,0.05
Lung 25.669.9 (n = 5) Spleen vs. LN: n.s. Liver vs. Lung: n.s.
CD38++ IgDneg BM 86.169.0 (n = 5) BM vs. Spleen: ,0.001 Spleen vs. Liver: n.s.
Spleen 38.5610.2 (n = 5) BM vs. LN: ,0.001 Spleen vs. Lung: ,0.001
LN 10.868.6 (n = 5) BM vs. Liver: ,0.001 LN vs. Liver: ,0.01
Liver 35.067.2 (n = 5) BM vs. Lung: ,0.001 LN vs. Lung: n.s.
Lung 12.662.8 (n = 5) Spleen vs. LN: ,0.001 Liver vs. Lung: ,0.01
CD38+ IgDneg BM 0.460.3 (n = 5) BM vs. Spleen: n.s. Spleen vs. Liver: n.s.
Spleen 1.260.4 (n = 5) BM vs. LN: ,0.05 Spleen vs. Lung: n.s.
LN 5.662.9 (n = 5) BM vs. Liver: n.s. LN vs. Liver: n.s.
Liver 1.561.1 (n = 5) BM vs. Lung: n.s. LN vs. Lung: n.s.
Lung 2.963.8 (n = 5) Spleen vs. LN: ,0.05 Liver vs. Lung: n.s.
CD38neg IgDneg BM 0.060.0 (n = 5) BM vs. Spleen: n.s. Spleen vs. Liver: n.s.
Spleen 0.060.0 (n = 5) BM vs. LN: n.s. Spleen vs. Lung: n.s.
LN 0.160.2 (n = 5) BM vs. Liver: n.s. LN vs. Liver: n.s.
Liver 0.160.2 (n = 5) BM vs. Lung: n.s. LN vs. Lung: n.s.
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[52,53]. The proportion of immature/atypical switched memory B
cells in the PB of BLT mice (20%612) was significantly greater
than in normal adult human PB (4%62) (p,0.05). Also, there
were fewer unswitched memory (3%62) and switched memory
(2%62) B cells in PB of BLT mice versus normal adult human PB
which exhibited significantly more unswitched (15%69) (p,
0.001) and switched memory B cells (17%69) (p,0.001)
(Figure 2A–B; Table 1). Furthermore, the proportion of memory
B cells in BLT mouse PB, recognized as such by their surface
phenotypes [CD38+IgDneg (1%60.7) and CD38negIgDneg
(0.5%61)], were significantly reduced when compared to adult
human PB (13%66) (p,0.001) and (8%65) (p,0.001), respec-
tively (Figure 2C–D; Table 1). Integrated analysis of all three
markers on BLT mouse peripheral blood B cells showed that ,
20% CD38++ IgDneg cells were CD27pos atypical switched
memory cells while the majority were CD27neg immature B cells
[54,55]. Overall, when compared to normal adult human PB, the
reduced frequency of mature B cells and the paucity of classical
unswitched/switched memory B cells in the PB of BLT mice
indicate that the majority of B cells in these animals do not
complete normal development.
B cell ontogeny in BM progresses normally in BLT mice,
but B cells do not mature into memory cells following
BM emigration
Since the BM is the primary lymphoid tissue where B cell
development occurs, we analyzed B cell ontogeny in BLT mouse
BM using surface and intracellular marker expression [56,57]. We
found that CD10+CD20neg pre-B cells, were the predominant
population in the BM of BLT mice (76%68) followed by
CD10+CD20+ immature B cells (17%67) (p,0.001) and
CD10negCD20+ mature B cells (6%64) (p,0.001) (Figure 3A–
B). The intracellular expression of terminal deoxynucleotide
transferase (TdT) is a phenotypic marker for early stages of B
cell development [58]. Accordingly, the intracellular expression of
TdT was greater in BLT mouse BM CD10+CD20neg pre-B cells
(19%610) when compared to CD10+CD20+ immature-B cells
(7%64) (p,0.001) or CD10neg CD20+ mature B cells (3%63) (p,
0.001) (Figure 3C–D). We also analyzed the expression of the pre-
B cell receptor surrogate light chain component l5 [59] and the
intracellular expression of IgM [56] in BM B cells. The majority of
B cells were CD10+ pre-B cells/immature B cells (90%65) while
the remaining B cells were mature CD10neg B cells (10%65) (p,
0.001) (Figure 3E–F). A greater proportion of pre-B cells/
immature B cells expressed l5 (24%67) in comparison to mature
B cells (5%64) (p,0.01) (Figure 3G–H) and the inverse was
observed regarding intracellular IgM expression. Specifically, the
proportion of CD10+ pre-B cells/immature B cells expressing
intracellular IgM was significantly lower (23%610) compared to
CD10neg mature B cells (66%614) (p,0.001) (Figure 3I–J). These
data show that B cell ontogeny in the BM of BLT mice progresses
as described for human BM.
Despite normal ontogeny, B cell maturation and development
in BLT mice appeared to progress to either the pre-naı¨ve or
mature naı¨ve stage and then stall. CD27/IgD co-expression
patterns revealed that both unswitched and switched memory B
cells were rare in BLT mouse BM (0.1%60.1; 0.6%60.3), spleen
(1%61; 0.7%60.6), LN (3%61.7; 5%65), liver (0.5%60.2;
1.3%60.8) and lung (0.7%60.7; 1%62) (Figure 4A–B; Table 2).
These systemic observations were confirmed with a complemen-
tary staining strategy. Specifically, memory B cells (defined as
CD38+ IgDneg and CD38neg IgDneg) were rare in the BM, spleen,
LN, liver and lung of BLT mice (,1% in all tissues) (Figure 4E–F;
Table 2). These data, together with the PB data presented above,
indicate that human B cells in BLT mice successfully emigrate
from the BM to the periphery where they fail to mature into
classical unswitched/switched memory B cells. This stall in B cell
differentiation in BLT mice could result from limited antigenic
stimulation associated with their specific pathogen-free housing
conditions [22,28].
Immunization led to increased numbers of switched
memory B cells in BLT mouse tissues
To test the hypothesis that antibody production in BLT mice
could be improved with specific antigen stimulation, BLT mice
were immunized intraperitoneally with conjugated phosphoryl-
choline - keyhole limpet hemocyanin (PC-KLH [60]) every other
week for a total of four immunizations (Figure 5A). During the
immunization series, we analyzed the peripheral B cell populations
longitudinally and observed gradual increases in PB unswitched
and classical switched memory B cell levels following immuniza-
tion (Figure 5B–C). Furthermore, examinations of B cells before
and after immunization according to CD38 and IgD co-expression
patterns indicated that mature and memory B cell populations
increased in the peripheral blood as a result of repeated
immunizations (Figures 5D–E; Table 3). Integrated analysis of
all three markers also showed an increased proportion of atypical
switched memory cells (i.e. CD38++ IgDneg cells expressing CD27)
in the peripheral blood following the immunizations (Figures 5F)
[54,55]. The classical and atypical switched memory cells present
in the peripheral blood following immunization likely account for
Table 2. Cont.
Tissue BLT Mice
1 way ANOVA Bonferroni’s multiple comparisons
tests
Lung 0.460.7 (n = 5) Spleen vs. LN: n.s. Liver vs. Lung: n.s.
Data presented as Mean 6 SD.
n.s. = not significantly different.
Immature B/Atypical switched memory B = CD27neg IgDneg.
Naı¨ve Mature B = CD27neg IgD+.
Transitional B/Mature Naı¨ve B = CD27+ IgD+.
Switched Memory IgM + B/Plasmablasts = CD27+ IgDneg.
doi:10.1371/journal.pone.0108663.t002
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the antigen-specific antibodies present in plasma following
immunization (Figures 5G).
Next, we analyzed tissues of immunized BLT mice and
compared their B cells to those derived from naive BLT mice.
We observed that memory B cell numbers increased in each tissue
evaluated versus non-immunized animals (Figure 6A; Table 3).
Similarly, CD38 and IgD co-expression patterns indicated that
mature and memory B cell populations increased throughout the
body as a result of the immunizations (Figures 6B; Table 3).
Moreover, integrated analysis of all three markers also showed an
increased proportion of atypical switched memory cells (i.e.
CD38++ IgDneg cells expressing CD27) in the spleen, LN, liver
and lung following the immunizations (Figures 6C) [54,55].
However, we did not observe typical lymphoid architecture in
the secondary lymphoid tissues of immunized NSG-BLT mice
(Figures 6D).
Finally, we performed ELISPOT analyses using cells isolated
from BM, spleen, LN, liver and lungs of immunized BLT mice to
Figure 5. Repeated immunizations with PC-KLH induced B cell differentiation in BLT mouse peripheral blood towards mature
phenotypes and increased plasma antigen-specific IgM. (A) Immunization schedule. (B–E) The B cell populations in the PB of BLT mice (n = 7)
were characterized before, during and after repeated PC-KLH immunizations. Representative flow cytometry analyses for CD27 and IgD expression on
PB B cells (B) and longitudinal analysis of B cell populations (C) are shown. Similarly, (D–E) depict representative flow cytometry and longitudinal data
regarding CD38 and IgD expression of PB B cells. (F) The percentage of CD38++IgDneg B cells that also express CD27 was calculated pre- and post-
immunization to determine the contribution of atypical switched memory B cells to the CD27negIgDneg population in (B). (G) Plasma levels of antigen-
specific IgM and IgG were measured longitudinally throughout the course of repeated PC-KLH immunizations (n = 7).
doi:10.1371/journal.pone.0108663.g005
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Table 3. Comparison of B cell populations between naı¨ve and PC-KLH immunized BLT mice using CD27/IgD and CD38/IgD co-
expression patterns.
Tissue BLT Mice* Immunized BLT Mice t-test
CD27/IgD Immature B/Atypical switched memory B BM 85.768.8 (n = 5) 82.4613.4 (n = 7) n.s.
Spleen 38.2610.3 (n = 5) 32.9616.4 (n = 7) n.s.
LN 11.069.4 (n = 5) 11.067.6 (n = 7) n.s.
Liver 34.867.6 (n = 5) 38.7616.4 (n = 7) n.s.
Lung 13.963.5 (n = 5) 17.366.6 (n = 7) n.s.
Transitional B/Mature Naı¨ve B BM 13.568.7 (n = 5) 11.7612.7 (n = 7) n.s.
Spleen 59.869.2 (n = 5) 23.8629.3 (n = 7) ,0.05
LN 81.3611.2 (n = 5) 70.1611.6 (n = 7) n.s.
Liver 63.567.7 (n = 5) 39.1623.1 (n = 7) ,0.05
Lung 84.265.7 (n = 5) 56.0620.9 (n = 7) ,0.05
Unswitched Memory B BM 0.160.1 (n = 5) 0.660.4 (n = 7) ,0.01
Spleen 1.261.0 (n = 5) 5.665.2 (n = 7) n.s.
LN 3.061.7 (n = 5) 8.062.7 (n = 7) ,0.01
Liver 0.560.2 (n = 5) 1.660.7 (n = 7) ,0.01
Lung 0.760.7 (n = 5) 3.663.5 (n = 7) n.s.
Switched Memory IgM + B/Plasmablasts BM 0.660.3 (n = 5) 5.363.2 (n = 7) ,0.01
Spleen 3.760.6 (n = 5) 37.7623.2 (n = 7) ,0.01
LN 4.764.9 (n = 5) 10.966.5 (n = 7) n.s.
Liver 1.360.8 (n = 5) 20.7614.1 (n = 7) ,0.05
Lung 1.362.0 (n = 5) 23.2617.0 (n = 7) ,0.05
CD38/IgD CD38neg IgD+ BM 0.160.1 (n = 5) 2.162.6 (n = 7) n.s.
Spleen 0.660.4 (n = 5) 3.664.6 (n = 7) n.s.
LN 0.560.4 (n = 5) 9.265.7 (n = 7) ,0.01
Liver 0.660.4 (n = 5) 7.865.5 (n = 7) ,0.05
Lung 1.360.8 (n = 5) 13.1610.9 (n = 7) ,0.05
CD38+ IgD+ BM 6.964.5 (n = 5) 8.468.6 (n = 7) n.s.
Spleen 37.169.5 (n = 5) 20.8622.9 (n = 7) n.s.
LN 73.617.7 (n = 5) 67.369.1 (n = 7) n.s.
Liver 43.2610.0 (n = 5) 30.6616.9 (n = 7) n.s.
Lung 59.6611.1 (n = 5) 41.9617.2 (n = 7) n.s.
CD38++ IgD+ BM 6.864.4 (n = 5) 2.362.3 (n = 7) ,0.05
Spleen 24.262.7 (n = 5) 6.163.8 (n = 7) ,0.001
LN 11.769.0 (n = 5) 8.165.1 (n = 7) ,0.05
Liver 21.464.0 (n = 5) 50.3623.5 (n = 7) ,0.001
Lung 25.669.9 (n = 5) 25.7622.9 (n = 7) ,0.01
CD38++ IgDneg BM 86.169.0 (n = 5) 86.0613.9 (n = 7) n.s.
Spleen 38.5610.2 (n = 5) 63.2627.1 (n = 7) n.s.
LN 10.868.6 (n = 5) 8.165.1 (n = 7) n.s.
Liver 35.067.2 (n = 5) 50.3623.5 (n = 7) n.s.
Lung 12.662.8 (n = 5) 25.7622.9 (n = 7) n.s.
CD38+ IgDneg BM 0.460.3 (n = 5) 1.461.0 (n = 7) n.s.
Spleen 1.260.4 (n = 5) 6.364.5 (n = 7) ,0.05
LN 5.662.9 (n = 5) 11.867.9 (n = 7) n.s.
Liver 1.561.1 (n = 5) 7.164.2 (n = 7) ,0.05
Lung 2.963.8 (n = 5) 9.367.0 (n = 7) n.s.
CD38neg IgDneg BM 0.060.0 (n = 5) 0.460.3 (n = 7) ,0.05
Spleen 0.060.0 (n = 5) 1.460.8 (n = 7) ,0.01
LN 0.160.2 (n = 5) 1.760.5 (n = 7) ,0.001
Liver 0.160.2 (n = 5) 5.364.1 (n = 7) ,0.05
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quantitate IgM- and IgG-producing plasma cells specific for PC or
KLH. The numbers of plasma cells producing IgM specific for PC
were similar in all tissues analyzed (p = n.s. for all comparison)
(Figure 7-right column). In addition, the numbers of plasma cells
producing IgM specific for PC in the BM and liver were
significantly greater than the other 3 categories of plasma cells
quantitated in each tissue (p,0.001 for all comparisons) which
provides evidence of a defect in isotype switching in BLT mouse B
cells (Figure 7-bottom row).
Discussion
Primary antibody deficiency is associated with reduced serum
IgG and IgA, often accompanied by reduced serum IgM [12].
These disorders, which include CVID, result from a spectrum of B
cell abnormalities caused by various genetic defects which may
affect T, B and potentially other cells [3–5,8–11]. Here, we
examined the suitability of BLT humanized mice to function as an
in vivo small animal model of primary antibody deficiency. We
determined that these patients and BLT mice share remarkable
similarities in their humoral immune system development and
function.
We began this study with a baseline characterization of humoral
immunity in naı¨ve BLT mice. We found that BLT mice exhibited
profound hypogammaglobulinemia (Figure 1A) and an absence of
memory B cells (Figures 2 and 4). Thus, B cells emigrated from the
BM to peripheral tissues, but did not differentiate into un-
switched/switched memory B cells or produce IgG. Next, we
sought to stepwise verify the stages of normal B cell development
in BLT mice. To do this, we performed a comprehensive analysis
of B cell development and differentiation in this model. In the BM
of BLT mice, we found that B cell ontogeny progressed as it does
in normal human BM (Figure 3) [11,56–59]. Together these data
show that B cells in BLT mice develop normally in the BM and
emigrate to other tissues throughout the body, but B cell
maturation is incomplete as the cells do not further differentiate
into classical unswitched/switched memory B cells.
This stall in B cell differentiation in BLT mice could be the
result of atypical lymphoid architecture in secondary lymphoid
tissues that may impede isotype switching (Figure 1C) although
recent data suggest that B cell maturation can be completed
outside of germinal centers [61]. Alternatively, the stall in B cell
differentiation in BLT mice could result from limited antigenic
stimulation associated with their specific pathogen-free housing
conditions [22,28]. To address this possibility, we performed
repeated PC-KLH immunizations of BLT mice. We observed
changes in the B cell populations of the PB and tissues including
increased levels of classical unswitched, classical switched and
atypical unswitched memory B cells (Figures 5&6). With these
increases, we also observed antigen-specific humoral responses
that increased over time (Figure 5G) and robust numbers of PC-
specific IgM producing plasma cells in tissues (Figure 7). However,
we did not observe improvements in lymphoid architecture in the
spleen or lymph nodes (Figure 6D), nor did we detect antigen-
specific IgG producing plasma cells in tissues (Figure 7). The
marginal improvements in B cell function observed in BLT mice
following PC-KLH immunization are reminiscent of both
immunized CVID patients who may develop IgM, but not IgG,
responses to the vaccine antigens [10,52,62] and pediatric severe
combined immunodeficiency (SCID) patients who receive alloge-
neic hematopoietic stem cell transplants but do not gain normal B
cell function despite multiple and varied antigen stimulations and
infections [63]. When taken together these observations indicate
that BLT mice exhibit numerous important primary antibody
deficiency patient phenotypes and can serve as a robust, small
animal model of these disorders in humans.
No single animal model is likely to recapitulate all aspects of
primary antibody deficiency in humans. Nevertheless, small
animal models could be valuable tools in the efforts to understand,
diagnose and treat such primary immunodeficiencies [20]. Herein,
we have identified remarkable similarities between the humoral
immune systems of primary antibody deficiency patients and those
in BLT mice: (i) hypogammaglobulinemia; (ii) normal B cell
ontogeny in BM; and (iii) poor antigen-specific IgG response to
immunization. Advantages of the BLT model of primary antibody
deficiency include the facts that: (i) human B and T cells are
interacting in vivo in a tractable small animal model; (ii) HLA-
restricted T-cells are present to help with B cell isotype class
switching [22,28,64–66]; and (iii) the observed paucity of switched
memory B cells is not due a defined monogenic defect but is the
expression of a more complex dysregulation. Elucidation of
mechanisms responsible for hypogammaglobulinemia in BLT
mice may provide insights into the underlying mechanisms
responsible for primary antibody deficiency in patients. Because
current hypogammaglobulinemia therapy is primarily limited to
passive immunoglobulin transfer and treatment of recurrent
infections with antimicrobials [15], strategies developed to
overcome hypogammaglobulinemia in the BLT model may
readily translate into novel clinical interventions that could
actively increase antibody production in patients and improve
prognoses.
Table 3. Cont.
Tissue BLT Mice* Immunized BLT Mice t-test
Lung 0.460.7 (n = 5) 13.1610.9 (n = 7) ,0.05
*Data for BLT mice also included in Table 2.
Data presented as Mean 6 SD.
n.s. = not significantly different.
Immature B/Atypical switched memory B = CD27neg IgDneg.
Naı¨ve Mature B = CD27neg IgD+.
Transitional B/Mature Naı¨ve B = CD27+ IgD+.
Switched Memory IgM + B/Plasmablasts = CD27+ IgDneg.
doi:10.1371/journal.pone.0108663.t003
Hypogammaglobulinemia in BLT Humanized Mice
PLOS ONE | www.plosone.org 11 October 2014 | Volume 9 | Issue 10 | e108663
Figure 6. Repeated immunizations with PC-KLH induced B cell differentiation in BLT mouse tissues towards mature phenotypes.
(A–B) B cell populations in the BM, spleen, LN, liver and lungs were characterized in naı¨ve and immunized BLT mice. CD27 and IgD (A) (naı¨ve, n = 5;
immunized, n = 7 for all tissues; t-tests) and CD38 and IgD (C) (naı¨ve, n = 5; immunized, n = 7; t-tests) co-expression patterns revealed increased levels
of CD19+ cells exhibiting mature phenotypes throughout the body following the repeated PC-KLH immunizations. (C) The percentage of
CD38++IgDneg B cells that also express CD27 was calculated in naive BLT mice and PC-KLH immunized BLT mice to determine the contribution of
atypical switched memory B cells to the CD27negIgDneg populations from each tissue in (A). (D) Sections from spleen (left) and lymph node (right) of
PC-KLH immunized BLT mice analyzed for lymphoid architecture via H&E staining. Scale bars = 50 mm in all images. Boxes indicate the areas that are
shown at higher magnification in the images below. * indicates a p value less than 0.05. ** indicates a p value less than 0.01. *** indicates a p value
less than 0.001. Comprehensive statistical analyses are presented in Table 3.
doi:10.1371/journal.pone.0108663.g006
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